In a clinical study, IDH1 and IDH2 mutations were observed in 16%–17% of patients with AML, in around 20% of angioimmunoblastic T-cell lymphomas (AITL) with worse prognosis [29], and in some low-frequency cancer malignancies [30,31,32,33]. Here, IDH2 is linked to acute myeloid leukemia.